Becoming the new editor for CA: The future is now
Click on the article title to read more.
Related Articles
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types
Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer…
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types
Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer…
Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children’s Oncology Group trials
Among patients with localized rhabdomyosarcoma (RMS), young patients and females had improved overall survival (OS). The OS of localized extremity RMS treated on D9803 was…
Cabozantinib benefits patients with advanced neuroendocrine tumors
Click on the article title to read more.
Low‐risk oncocytic renal neoplasm: A useful cytologic diagnosis
The proposed diagnostic category of “low-risk oncocytic renal neoplasm” consists of both oncocytomas and a subset of chromophobe renal cell carcinomas but has a 5-year…
New standard of care for patients with asymptomatic brain metastases from melanoma
Click on the article title to read more.
Deep learning model for predicting immunotherapy response in patients with advanced NSCLC
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, study findings demonstrate a strong…
Cancer treatment and survivorship statistics, 2025: An urgent call to optimize health after cancer
Click on the article title to read more.
Top advances of the year: Neoadjuvant immunotherapy in melanoma
Overall, much progress was made in 2024 in the realm of neoadjuvant immunotherapy including the firm establishment of neoadjuvant immunotherapy as superior to only adjuvant…